For Internal Use 2014 APR 30 PM 1: 29

Only Sec File No. 9-

SEC / MR

Submit 1 Original and 9 Copies

UNITED STATES

SEC

OMB APPROVAL

OMB Number: 3235-0504

Mail Processin Expires: August 31, 2010 Estimated average burden hours per response.....3.60

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Section APR 302014

FORM 19b-4(e)

Washington DC

Information Required of a Self-Regulatory Organization Listing and Trading a New Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934

READ ALL INSTRUCTIONS PRIOR TO COMPLETING FOR

Part I

Initial Listing Report



1. Name of Self-Regulatory Organization Listing New Derivative Securities Product: NASDAQ OMX BX, Inc. (traded pursuant to unlisted trading privileges)

- 2. Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.): **Open End Management Investment Company**
- 3. Class of New Derivative Securities Product:

Exchange Traded Fund

4. Name of Underlying Instrument:

WisdomTree Japan Hedged Health Care Index

- 5. If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow-Based: **Broad-based**
- 6. Ticker Symbol(s) of New Derivative Securities Product:
- 7. Market or Markets Upon Which Securities Comprising Underlying Instrument Trades: Listed on: CME Group, Jasdaq, Tokyo Stock Exchange
- 8. Position Limits of New Derivative Securities Product (if applicable): Regular way trades settle on T + 3 (cash settled)
- 9. Position Limits of New Derivative Securities Product (if applicable): N/A

Part II

Execution

The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.

Name of Official Responsible for Form:

Joan Conley

Title:

Secretary

Telephone Number:

301-978-8735

Manual Signature of Official Responsible for Form:

Date: April 10, 2014

SEC 2449 (6-01)

Securities Entremed

145.4(e)

Public Availability:

APR 3 0 2014